Scott Henry


Biodelivery: We Remain On The Sidelines Pending A Few More Weeks Of Bunavail Prescriptions, Say Roth Capital

Roth Capital analyst Scott Henry maintained a Neutral rating on Biodelivery Sciences (NASDAQ:BDSI) with a $20 price target, which represents a potential upside …

Roth Capital Reiterates Buy On Apricus Biosciences Following 3Q14 Results

Roth Capital analyst Scott Henry reiterated a Buy rating on Apricus Biosciences (NASDAQ:APRI) with a $4 price target, following the company’s third quarter results, which were within …

Synergy Pharmaceuticals: Dilution Painful But Pipeline Is Advancing, Says Roth Capital

In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on Synergy Pharmaceuticals (NASDAQ:SGYP), but reduced his price …

Roth Capital Maintains Buy On Catalyst Pharmaceutical Following 3Q14 Update

Roth Capital analyst Scott Henry maintained a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $6.00 price target, following the company’s third-quarter results, …

Roth Capital Reiterates Buy On Tonix Pharmaceuticals As Risk-Reward Is Favorable

Roth Capital analyst Scott Henry reiterated a Buy rating on Tonix Pharmaceuticals (NASDAQ:TNXP) with a $10 price target, following the company’s third-quarter results. reporting a 3Q14 EPS …

Roth Capital Cuts Alexza Pharmaceuticals Price Target Following Earnings

Roth Capital analyst Scott Henry maintained a Neutral rating on Alexza Pharmaceuticals (NASDAQ:ALXA), and reduced his price target to $2.50 (from $5.

Roth Capital Moves To The Sideline On Salix Pharmaceuticals; Cuts PT To $95

In a research report issued today, Roth Capital analyst Scott Henry downgrades shares of Salix Pharmaceuticals (NASDAQ:SLXP) from Buy to Hold and reduced his price …

Roth Capital Maintains Buy On Discovery Laboratories Following 3Q14 Update

In a research report sent to investors today, Roth Capital analyst Scott Henry maintained a Buy rating on Discovery Laboratories (NASDAQ:DSCO) with a …

Roth Capital Raises Lannett Company Price Target On The Back Of FY1Q15 Results

Roth Capital analyst Scott Henry maintained a Buy rating on Lannett Company (NYSE:LCI) with a price target of $66, as the company reported FY1Q15 …

Roth Capital Reaffirms Buy On Flamel, Sees 67% Upside

In a research report published issued today, Roth Capital analyst Scott Henry reaffirmed a Buy rating on Flamel (NASDAQ:FLML) with a price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts